{
    "hands_on_practices": [
        {
            "introduction": "Before initiating any medication, a thorough safety assessment is paramount. For tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a cornerstone of oral PrEP, assessing renal function is a critical first step due to potential nephrotoxicity. This exercise hones your ability to apply the Cockcroft-Gault equation to estimate creatinine clearance, a fundamental skill for determining patient eligibility and ensuring safe prescribing .",
            "id": "4848814",
            "problem": "A $64$-year-old cisgender woman with a body weight of $62$ kg, a body mass index of $23$ kg/m$^2$, and a stable serum creatinine (SCr) of $1.1$ mg/dL presents for initiation of daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP). There is no evidence of acute kidney injury. Using the Cockcroft-Gault method with the standard female correction factor and using actual body weight, estimate her creatinine clearance (CrCl) in mL/min. According to widely used prescribing criteria, initiation of daily TDF/FTC for PrEP requires a minimum CrCl of $60$ mL/min. First, compute CrCl and round it to four significant figures in mL/min. Then define the eligibility indicator $E$ such that $E=1$ if the patient is eligible for daily TDF/FTC PrEP on the basis of the CrCl threshold (that is, CrCl $\\geq 60$ mL/min), and $E=0$ otherwise. Provide the single value of $E$ as your final answer (dimensionless).",
            "solution": "The problem statement is evaluated to be valid. It is scientifically grounded in clinical pharmacology, well-posed with all necessary data provided, and objective in its language. The task is a direct application of a standard medical formula, the Cockcroft-Gault equation, to determine a patient's estimated creatinine clearance ($CrCl$) and subsequently decide on their eligibility for a specific medication based on a given threshold.\n\nThe Cockcroft-Gault equation is used to estimate creatinine clearance. The general form of the equation is:\n$$ CrCl = \\frac{(140 - \\text{Age}) \\times \\text{Weight}}{72 \\times SCr} $$\nwhere age is in years, weight is in kilograms ($kg$), and a patient's serum creatinine ($SCr$) is in milligrams per deciliter ($mg/dL$).\n\nThe problem specifies that the patient is a cisgender woman, for whom a correction factor of $0.85$ must be applied. The formula thus becomes:\n$$ CrCl_{\\text{female}} = 0.85 \\times \\frac{(140 - \\text{Age}) \\times \\text{Weight}}{72 \\times SCr} $$\n\nThe givens from the problem statement are:\n- Age: $A = 64$ years\n- Actual body weight: $W = 62$ $kg$\n- Serum creatinine: $SCr = 1.1$ $mg/dL$\n\nWe substitute these values into the formula for a female patient:\n$$ CrCl = 0.85 \\times \\frac{(140 - 64) \\times 62}{72 \\times 1.1} $$\n\nFirst, we evaluate the expression inside the parentheses:\n$$ 140 - 64 = 76 $$\n\nNext, we calculate the numerator and the denominator of the fraction:\n$$ \\text{Numerator} = 76 \\times 62 = 4712 $$\n$$ \\text{Denominator} = 72 \\times 1.1 = 79.2 $$\n\nNow, we compute the value of the fraction:\n$$ \\frac{4712}{79.2} \\approx 59.494949... $$\n\nFinally, we apply the female correction factor of $0.85$:\n$$ CrCl = 0.85 \\times 59.494949... \\approx 50.570707... \\text{ mL/min} $$\n\nThe problem requires rounding the calculated $CrCl$ to four significant figures. The first four significant figures are $5$, $0$, $5$, and $7$. The fifth significant figure is $0$, so we do not round up.\n$$ CrCl_{\\text{rounded}} = 50.57 \\text{ mL/min} $$\n\nThe next step is to determine the eligibility indicator, $E$. The criteria for $E$ are defined as:\n- $E = 1$ if $CrCl \\geq 60$ $mL/min$\n- $E = 0$ if $CrCl < 60$ $mL/min$\n\nWe compare the calculated creatinine clearance, $50.57$ $mL/min$, to the eligibility threshold of $60$ $mL/min$.\n$$ 50.57 < 60 $$\nSince the patient's estimated $CrCl$ is less than $60$ $mL/min$, she does not meet the specified criterion for initiation of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).\n\nAccording to the definition provided, if $CrCl < 60$ $mL/min$, then the eligibility indicator $E$ is $0$.\nTherefore, $E = 0$.",
            "answer": "$$\\boxed{0}$$"
        },
        {
            "introduction": "After confirming eligibility, the clinical decision often shifts to selecting the optimal regimen for the individual patient. TDF/FTC and tenofovir alafenamide/emtricitabine (TAF/FTC) differ in their safety profiles, especially regarding bone and renal health. This practice problem demonstrates a quantitative, evidence-based method for comparing their impact on bone mineral density, enabling a more nuanced and patient-centered choice .",
            "id": "4848791",
            "problem": "A clinician is comparing two Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) regimens for a patient with low baseline fracture risk but concern for bone health: tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) versus tenofovir alafenamide (TAF) plus emtricitabine (FTC). The clinician wants a single precision-weighted composite of one-year absolute change in areal Bone Mineral Density (BMD) across two clinically relevant sites: total hip and lumbar spine. Baseline areal BMDs are $B_{H} = 1.00$ $\\mathrm{g/cm^2}$ at the total hip and $B_{S} = 1.20$ $\\mathrm{g/cm^2}$ at the lumbar spine. From well-conducted randomized studies, the estimated one-year proportional changes (as decimal fractions of baseline, negative indicating loss) are:\n- For TDF/FTC: $c_{H,\\mathrm{TDF}} = -0.015$ at the hip and $c_{S,\\mathrm{TDF}} = -0.010$ at the spine.\n- For TAF/FTC: $c_{H,\\mathrm{TAF}} = -0.002$ at the hip and $c_{S,\\mathrm{TAF}} = -0.001$ at the spine.\nAssume these site-specific changes apply deterministically to the given baselines. The dual-energy X-ray absorptiometry systemâ€™s reproducibility (standard error of measurement) at the hip and spine, respectively, is $\\sigma_{H} = 0.008$ $\\mathrm{g/cm^2}$ and $\\sigma_{S} = 0.010$ $\\mathrm{g/cm^2}$.\n\nDefine the composite absolute BMD change for a regimen $r$ as\n$$\n\\Delta B_{r} = \\tilde{w}_{H}\\,|c_{H,r}\\,B_{H}| + \\tilde{w}_{S}\\,|c_{S,r}\\,B_{S}|,\n$$\nwhere the precision weights are inverse-variance normalized,\n$$\n\\tilde{w}_{i} = \\frac{1/\\sigma_{i}^{2}}{(1/\\sigma_{H}^{2}) + (1/\\sigma_{S}^{2})}, \\quad i \\in \\{H,S\\}.\n$$\nUsing these inputs and definitions, calculate the expected difference in composite absolute BMD change over one year between TDF/FTC and TAF/FTC,\n$$\n\\Delta = \\Delta B_{\\mathrm{TDF}} - \\Delta B_{\\mathrm{TAF}},\n$$\nand express your final numeric answer in $\\mathrm{g/cm^2}$. Round your answer to four significant figures. In addition, briefly discuss the clinical significance of the computed difference for regimen selection in PrEP in an adult with bone health considerations.",
            "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in established knowledge regarding the effects of tenofovir-based regimens on bone mineral density, and the values provided are clinically realistic. The problem is well-posed, with all necessary data, constants, and definitions for calculating a unique solution using the provided model. The use of inverse-variance weighting to create a composite score is a standard and appropriate statistical technique.\n\nThe objective is to calculate the difference in the precision-weighted composite absolute bone mineral density (BMD) change between two regimens, TDF/FTC and TAF/FTC. The difference is defined as $\\Delta = \\Delta B_{\\mathrm{TDF}} - \\Delta B_{\\mathrm{TAF}}$.\n\nFirst, we calculate the precision weights, $\\tilde{w}_{H}$ and $\\tilde{w}_{S}$, which are based on the inverse of the measurement variance for each site. The standard errors of measurement are given as $\\sigma_{H} = 0.008 \\, \\mathrm{g/cm^2}$ and $\\sigma_{S} = 0.010 \\, \\mathrm{g/cm^2}$. The variances are $\\sigma_{H}^2$ and $\\sigma_{S}^2$.\n\nThe weights are defined as:\n$$\n\\tilde{w}_{i} = \\frac{1/\\sigma_{i}^{2}}{(1/\\sigma_{H}^{2}) + (1/\\sigma_{S}^{2})}, \\quad i \\in \\{H,S\\}\n$$\nLet's compute the inverse variances:\n$$\n\\frac{1}{\\sigma_{H}^{2}} = \\frac{1}{(0.008)^2} = \\frac{1}{0.000064} = 15625\n$$\n$$\n\\frac{1}{\\sigma_{S}^{2}} = \\frac{1}{(0.010)^2} = \\frac{1}{0.0001} = 10000\n$$\nThe sum of the inverse variances is:\n$$\n\\frac{1}{\\sigma_{H}^{2}} + \\frac{1}{\\sigma_{S}^{2}} = 15625 + 10000 = 25625\n$$\nNow, we can find the normalized weights:\n$$\n\\tilde{w}_{H} = \\frac{15625}{25625} = \\frac{25}{41}\n$$\n$$\n\\tilde{w}_{S} = \\frac{10000}{25625} = \\frac{16}{41}\n$$\nAs a check, $\\tilde{w}_{H} + \\tilde{w}_{S} = \\frac{25}{41} + \\frac{16}{41} = \\frac{41}{41} = 1$.\n\nNext, we calculate the absolute BMD change at each site for each regimen. The absolute change is $|c_{i,r} B_{i}|$. The baseline BMDs are $B_{H} = 1.00 \\, \\mathrm{g/cm^2}$ and $B_{S} = 1.20 \\, \\mathrm{g/cm^2}$.\n\nFor the TDF/FTC regimen ($r = \\mathrm{TDF}$):\nAbsolute change at the hip:\n$$\n\\Delta B_{H,\\mathrm{TDF}} = |c_{H,\\mathrm{TDF}}\\,B_{H}| = |-0.015 \\times 1.00| = 0.015 \\, \\mathrm{g/cm^2}\n$$\nAbsolute change at the spine:\n$$\n\\Delta B_{S,\\mathrm{TDF}} = |c_{S,\\mathrm{TDF}}\\,B_{S}| = |-0.010 \\times 1.20| = 0.012 \\, \\mathrm{g/cm^2}\n$$\n\nFor the TAF/FTC regimen ($r = \\mathrm{TAF}$):\nAbsolute change at the hip:\n$$\n\\Delta B_{H,\\mathrm{TAF}} = |c_{H,\\mathrm{TAF}}\\,B_{H}| = |-0.002 \\times 1.00| = 0.002 \\, \\mathrm{g/cm^2}\n$$\nAbsolute change at the spine:\n$$\n\\Delta B_{S,\\mathrm{TAF}} = |c_{S,\\mathrm{TAF}}\\,B_{S}| = |-0.001 \\times 1.20| = 0.0012 \\, \\mathrm{g/cm^2}\n$$\n\nNow, we compute the composite absolute BMD change, $\\Delta B_{r}$, for each regimen using the formula $\\Delta B_{r} = \\tilde{w}_{H}\\,|c_{H,r}\\,B_{H}| + \\tilde{w}_{S}\\,|c_{S,r}\\,B_{S}|$.\n\nFor TDF/FTC:\n$$\n\\Delta B_{\\mathrm{TDF}} = \\tilde{w}_{H} \\Delta B_{H,\\mathrm{TDF}} + \\tilde{w}_{S} \\Delta B_{S,\\mathrm{TDF}} = \\frac{25}{41}(0.015) + \\frac{16}{41}(0.012)\n$$\n$$\n\\Delta B_{\\mathrm{TDF}} = \\frac{1}{41}(0.375 + 0.192) = \\frac{0.567}{41} \\, \\mathrm{g/cm^2}\n$$\n\nFor TAF/FTC:\n$$\n\\Delta B_{\\mathrm{TAF}} = \\tilde{w}_{H} \\Delta B_{H,\\mathrm{TAF}} + \\tilde{w}_{S} \\Delta B_{S,\\mathrm{TAF}} = \\frac{25}{41}(0.002) + \\frac{16}{41}(0.0012)\n$$\n$$\n\\Delta B_{\\mathrm{TAF}} = \\frac{1}{41}(0.050 + 0.0192) = \\frac{0.0692}{41} \\, \\mathrm{g/cm^2}\n$$\n\nFinally, we calculate the difference $\\Delta = \\Delta B_{\\mathrm{TDF}} - \\Delta B_{\\mathrm{TAF}}$.\n$$\n\\Delta = \\frac{0.567}{41} - \\frac{0.0692}{41} = \\frac{0.567 - 0.0692}{41} = \\frac{0.4978}{41}\n$$\nPerforming the final division:\n$$\n\\Delta \\approx 0.012141463... \\, \\mathrm{g/cm^2}\n$$\nThe problem requires the answer to be rounded to four significant figures. The first non-zero digit is 1, so we keep it and the next three digits.\n$$\n\\Delta \\approx 0.01214 \\, \\mathrm{g/cm^2}\n$$\n\nThe question also requests a brief discussion of the clinical significance. The calculated difference, $\\Delta = 0.01214 \\, \\mathrm{g/cm^2}$, represents the additional precision-weighted composite BMD loss expected over one year with the TDF/FTC regimen compared to the TAF/FTC regimen for this specific patient profile and model. This difference, while numerically small, is clinically meaningful. It is greater than the standard error of measurement at both the hip ($\\sigma_{H} = 0.008 \\, \\mathrm{g/cm^2}$) and the spine ($\\sigma_{S} = 0.010 \\, \\mathrm{g/cm^2}$), indicating that the differential effect of the two drugs on bone is larger than the measurement \"noise\" of the densitometer. For a patient with concerns about bone health, even in the absence of high baseline fracture risk, this quantifiable difference provides strong evidence to favor the TAF/FTC regimen. The choice of TAF/FTC minimizes the iatrogenic bone loss associated with PrEP, aligning with the \"bone-sparing\" strategy often recommended in clinical guidelines for patients with risk factors for or established bone disease. This calculation provides a quantitative justification for this common clinical recommendation.",
            "answer": "$$\\boxed{0.01214}$$"
        },
        {
            "introduction": "The success of oral PrEP hinges on patient adherence, but effective counseling goes beyond simple instructions. Understanding the 'why' behind dosing recommendations is key. This exercise delves into the pharmacological principles of PrEP by using a pharmacokinetic model to calculate the minimum adherence needed to maintain protective drug levels, providing a scientific foundation for your patient education .",
            "id": "4848742",
            "problem": "A clinician is designing a dosing schedule for oral Tenofovir Disoproxil Fumarate/Emtricitabine pre-exposure prophylaxis (PrEP) and will monitor intracellular tenofovir-diphosphate (TFV-DP) using dried blood spots. Assume the following scientifically grounded pharmacokinetic features.\n\n1. First-order elimination of TFV-DP with half-life $t_{1/2} = 17$ days; hence elimination follows $dC/dt = -k\\,C$ for concentration $C(t)$, where $k$ is the elimination rate constant.\n2. Each oral dose instantaneously increases the measured TFV-DP in dried blood spots by $S = 55$ fmol/punch immediately after dosing.\n3. Doses are spaced evenly over a $7$-day week with dosing interval $\\tau$ days, so the adherence frequency is $f = 7/\\tau$ doses/week.\n4. After sufficient time, the system reaches a periodic steady state where concentrations just after and just before dosing repeat each interval.\n5. A clinically protective threshold requires the steady-state trough (the concentration immediately prior to a dose) to be at least $C_{\\mathrm{thr}} = 700$ fmol/punch.\n\nStarting only from first-order elimination and linear superposition principles, derive the condition for the steady-state trough and compute the minimum adherence $f$ (in doses/week) such that the steady-state trough equals $C_{\\mathrm{thr}}$. Round your final numerical answer to three significant figures and express it in doses/week.",
            "solution": "The user has provided a problem statement that must first be validated for scientific soundness, completeness, and objectivity before a solution is attempted.\n\n### Step 1: Extract Givens\n- The elimination of TFV-DP is a first-order process: $\\frac{dC}{dt} = -k\\,C$, where $C(t)$ is the concentration and $k$ is the elimination rate constant.\n- The half-life of elimination is $t_{1/2} = 17$ days.\n- Each oral dose results in an instantaneous increase in concentration of $S = 55$ fmol/punch.\n- Doses are administered at a constant interval of $\\tau$ days.\n- Adherence frequency is defined as $f = \\frac{7}{\\tau}$ doses/week.\n- The system reaches a periodic steady state after a sufficient duration of dosing.\n- The clinically protective threshold is a steady-state trough concentration of at least $C_{\\mathrm{thr}} = 700$ fmol/punch.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding:** The problem is grounded in standard pharmacokinetic modeling. First-order elimination is a common and valid model for drug clearance. The concept of half-life, dosing intervals, and steady-state peak and trough concentrations are fundamental principles in pharmacology. The given half-life for intracellular tenofovir-diphosphate is consistent with published scientific literature. The problem is scientifically sound.\n- **Well-Posedness:** The problem is well-posed. It provides all necessary parameters ($t_{1/2}$, $S$, $C_{\\mathrm{thr}}$) and relationships ($f = 7/\\tau$) to derive a unique solution for the minimum adherence frequency $f$.\n- **Objectivity:** The problem statement is entirely objective, using precise, quantitative language without any subjective or ambiguous terms.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically grounded, well-posed, and objective. A solution will be derived.\n\n### Derivation of the Solution\nThe concentration $C(t)$ of the drug follows the first-order elimination kinetic model $\\frac{dC}{dt} = -k\\,C$. The solution to this differential equation is $C(t) = C(0)\\exp(-kt)$, where $C(0)$ is the initial concentration.\n\nThe relationship between the elimination rate constant $k$ and the half-life $t_{1/2}$ is derived from the definition of half-life, where $C(t_{1/2}) = \\frac{1}{2}C(0)$.\n$$\n\\frac{1}{2}C(0) = C(0)\\exp(-k t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k t_{1/2})\n$$\nTaking the natural logarithm of both sides gives:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2} \\implies -\\ln(2) = -k t_{1/2}\n$$\nThus, the elimination rate constant is:\n$$\nk = \\frac{\\ln(2)}{t_{1/2}}\n$$\n\nNow, we model the concentration over time with repeated dosing at intervals of $\\tau$. Let $C_n^{\\text{trough}}$ be the trough concentration immediately before the $n$-th dose, and $C_n^{\\text{peak}}$ be the peak concentration immediately after the $n$-th dose.\nAfter the $n$-th dose is administered, the concentration instantaneously increases by $S$:\n$$\nC_n^{\\text{peak}} = C_n^{\\text{trough}} + S\n$$\nDuring the interval $\\tau$ until the next dose, the concentration decays exponentially:\n$$\nC_{n+1}^{\\text{trough}} = C_n^{\\text{peak}} \\exp(-k\\tau)\n$$\nSubstituting the expression for $C_n^{\\text{peak}}$ into the second equation yields a recurrence relation for the trough concentration:\n$$\nC_{n+1}^{\\text{trough}} = (C_n^{\\text{trough}} + S) \\exp(-k\\tau)\n$$\nAt steady state, the concentration profile becomes periodic, meaning the trough concentration is the same for every interval. We denote this steady-state trough concentration as $C_{\\text{ss}}^{\\text{trough}}$. Therefore, $C_{n+1}^{\\text{trough}} = C_n^{\\text{trough}} = C_{\\text{ss}}^{\\text{trough}}$. The recurrence relation becomes an algebraic equation:\n$$\nC_{\\text{ss}}^{\\text{trough}} = (C_{\\text{ss}}^{\\text{trough}} + S) \\exp(-k\\tau)\n$$\nWe solve for $C_{\\text{ss}}^{\\text{trough}}$:\n$$\nC_{\\text{ss}}^{\\text{trough}} = C_{\\text{ss}}^{\\text{trough}}\\exp(-k\\tau) + S\\exp(-k\\tau)\n$$\n$$\nC_{\\text{ss}}^{\\text{trough}} (1 - \\exp(-k\\tau)) = S\\exp(-k\\tau)\n$$\n$$\nC_{\\text{ss}}^{\\text{trough}} = \\frac{S\\exp(-k\\tau)}{1 - \\exp(-k\\tau)} = \\frac{S}{\\frac{1}{\\exp(-k\\tau)} - 1} = \\frac{S}{\\exp(k\\tau) - 1}\n$$\nThe problem requires the steady-state trough concentration to be at least $C_{\\mathrm{thr}}$. The minimum adherence corresponds to the case where the trough concentration is exactly equal to the threshold: $C_{\\text{ss}}^{\\text{trough}} = C_{\\mathrm{thr}}$.\n$$\nC_{\\mathrm{thr}} = \\frac{S}{\\exp(k\\tau) - 1}\n$$\nNow, we solve for the dosing interval $\\tau$:\n$$\n\\exp(k\\tau) - 1 = \\frac{S}{C_{\\mathrm{thr}}}\n$$\n$$\n\\exp(k\\tau) = 1 + \\frac{S}{C_{\\mathrm{thr}}}\n$$\n$$\nk\\tau = \\ln\\left(1 + \\frac{S}{C_{\\mathrm{thr}}}\\right)\n$$\n$$\n\\tau = \\frac{1}{k} \\ln\\left(1 + \\frac{S}{C_{\\mathrm{thr}}}\\right)\n$$\nSubstituting $k = \\frac{\\ln(2)}{t_{1/2}}$:\n$$\n\\tau = \\frac{t_{1/2}}{\\ln(2)} \\ln\\left(1 + \\frac{S}{C_{\\mathrm{thr}}}\\right)\n$$\nThis value of $\\tau$ is the maximum possible dosing interval that maintains the protective threshold. A smaller $\\tau$ would result in a higher trough concentration.\n\nThe adherence frequency is given by $f = \\frac{7}{\\tau}$ doses/week. The minimum required adherence $f$ corresponds to the maximum allowed interval $\\tau$.\n$$\nf = \\frac{7}{\\tau} = \\frac{7\\ln(2)}{t_{1/2} \\ln\\left(1 + \\frac{S}{C_{\\mathrm{thr}}}\\right)}\n$$\nWe are given the values $t_{1/2} = 17$ days, $S = 55$ fmol/punch, and $C_{\\mathrm{thr}} = 700$ fmol/punch. Substituting these into the expression for $f$:\n$$\nf = \\frac{7\\ln(2)}{17 \\ln\\left(1 + \\frac{55}{700}\\right)}\n$$\nNow, we compute the numerical value:\n$$\nf = \\frac{7\\ln(2)}{17 \\ln\\left(\\frac{700 + 55}{700}\\right)} = \\frac{7\\ln(2)}{17 \\ln\\left(\\frac{755}{700}\\right)}\n$$\n$$\nf \\approx \\frac{7(0.693147)}{17 \\ln(1.078571)} \\approx \\frac{4.852029}{17(0.075630)} \\approx \\frac{4.852029}{1.28571} \\approx 3.77410\n$$\nRounding the result to three significant figures gives $3.77$. The units are doses/week.",
            "answer": "$$\\boxed{3.77}$$"
        }
    ]
}